Results 171 to 180 of about 251,884 (333)
The potential for biased signalling in the P2Y receptor family of GPCRs
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk +2 more
wiley +1 more source
Synthesis, antioxidant and antimicrobial activities, molecular docking study of new pyrimidine derivatives. [PDF]
Khalaf HS +3 more
europepmc +1 more source
Pyrimidine base and ribonucleoside catabolic enzyme activities of thePseudomonas diminutagroup [PDF]
Thomas P. West
openalex +1 more source
Novel Pyrimidine-5-carboxamide Compounds as NNMT Inhibitors for Treating Diabetes
Ram W. Sabnis
openalex +2 more sources
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
A one step synthetic approach to L-pyrimidine nucleosides using Natural Phosphate coated with potassium iodide as catalyst [PDF]
Hassan B. Lazrek +4 more
openalex +1 more source
SLPI reduces the sensitivity of PDAC to gemcitabine by competing with FBW7 for binding to c‐Myc, thereby disrupting FBW7‐dependent ubiquitination and proteasomal degradation of c‐Myc, leading to increased c‐Myc stability and expression. SLPI knockdown could significantly increase gemcitabine sensitivity to gemcitabine‐induced direct cytotoxicity and NK
Haofei Chen +7 more
wiley +1 more source

